Model for classification of heart failure severity in patients with hypertrophic cardiomyopathy using a deep neural

Sanshiro Togo1, Yuki Sugiura1, Sayumi Suzuki2

  • 1Hamamatsu University School of Medicine, Hamamatsu, Japan.

Open Heart
|December 6, 2023
PubMed

Insights

Deep learning models can now classify heart failure severity in hypertrophic cardiomyopathy patients using ECG data. This approach shows promise for non-invasively assessing disease progression and guiding treatment strategies.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Artificial Intelligence

Background:

  • Electrocardiogram (ECG) abnormalities are characteristic of hypertrophic cardiomyopathy (HCM).
  • While ECG aids in risk stratification for arrhythmias, its utility in determining heart failure (HF) severity using deep learning (DL) remains underexplored.
  • Identifying HF severity is crucial for managing HCM patients.

Purpose of the Study:

  • To develop and evaluate a DL model for classifying HF severity in HCM patients using 12-lead ECG data.
  • To assess the model's performance in distinguishing between different levels of HF severity.
  • To explore the potential of ECG-based DL for non-invasive HF assessment in HCM.

Main Methods:

  • A residual neural network was developed using 12-lead ECG data from HCM and non-HCM patients.
  • HF severity was categorized using New York Heart Association functional class, N-terminal prohormone of brain natriuretic peptide levels, and Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 scores.
  • Transfer learning was employed, pre-training the model on the PTB-XL ECG dataset to address limited sample sizes.

Main Results:

  • The DL model achieved a weighted average F1 score of 0.745 and precision of 0.750 for mild-to-moderate HF classification.
  • Similar performance was observed when grouping patients based on KCCQ-12 scores.
  • Analysis revealed that QRS waves were key indicators for mild-to-moderate HF, while patterns were more variable for severe HF.

Conclusions:

  • A deep neural network model effectively classifies HF severity in HCM patients using 12-lead ECG data.
  • The developed DL algorithm shows potential as a valuable tool for assessing HF status in HCM.
  • This approach may facilitate non-invasive monitoring and management of heart failure in HCM.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594